{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-001271","form_type":"8-K","ticker":"ENTXW","cik":"0001638097","company_name":"Entera Bio Ltd.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.954217+00:00","generated_at":"2026-06-17T07:56:44.607486+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Entera Bio posts 2022 net loss of $13.1M; cash runway into Q3 2024; FDA accepts Type D meeting for EB613","bullets":["Net loss $13.1M ($0.45/share) vs $12.2M ($0.47/share) in 2021; revenues $134K, down from $571K.","Cash and equivalents $12.3M; expects runway into Q3 2024, excluding Phase 3 EB613 funding.","FDA accepted Type D meeting to confirm placebo-controlled Phase 3 design with TH BMD endpoint for EB613.","EB613 (oral teriparatide) positioned as first daily tablet anabolic therapy for osteoporosis; Phase 2 results positive.","New formulation EB612 (PTH(1-34) for hypoparathyroidism) entering Phase 1 PK study, targeting Phase 2 in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-001271","json":"https://secwatch.observer/filing/0001178913-23-001271.json","markdown":"https://secwatch.observer/filing/0001178913-23-001271.md","text":"https://secwatch.observer/filing/0001178913-23-001271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/0001178913-23-001271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:56:44.607486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea9e5fc51bccf5c77e8e21e168b145a541a7ec96","claim":"Entera Bio Ltd. reported the fiscal year ended December 31, 2022 results: revenue $134,000, net income $13.1 million, EPS $0.45 per ordinary share (basic and diluted).","evidence_excerpt":"stated Miranda Toledano, Chief Executive Officer of Entera. Financial Results for the year Ended December 31, 2022 Revenues for the year ended December 31, 2022 and 2021 were $134,000 and $571,000, respectively, mainly attributable to research and development, or R&D services provided to Amgen and other third parties under material transfer agreements. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891323001271/0001178913-23-001271-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$134,000"},{"label":"Net income","value":"$13.1 million"},{"label":"EPS","value":"$0.45 per ordinary share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}